Johnson & Johnson’s Janssen Pharmaceutical Cos. and Legend Biotech Corp. have unblinded their Phase III study of the BCMA-targeted CAR-T therapy Carvykti (ciltacabtagene autoleucel) in patients with second- to fourth-line multiple myeloma after the trial met its primary endpoint. But even if the data give Carvykti a leg up over its main competitor, 2seventy Bio, Inc./Bristol Myers Squibb Company’s Abecma (idecabtagene vicleucel), ongoing production and logistical issues may make the rollout to a larger patient population particularly challenging.
J&J/Legend’s Carvykti Data Show Earlier-Line Efficacy As Commercial Headwinds Remain
The companies unblinded data from CARTITUDE-4, which met its primary endpoint, but analysts citing KOLs said they continue to face issues with limited manufacturing slots and out-of-spec product.
More from Immuno-oncology
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.
• By
Increasingly focused on maximizing and accelerating the progress of its PD-L1 x VEGF inhibitor BNT357, the company expects new partnerships to be announced this year.
• By
Sun is acquiring Checkpoint Therapeutics, opening up opportunities to build out its strategy in the onco-derm segment with the US firm’s FDA-approved anti-PD-L1 mAb.
More from Anticancer
• By
Miltenyi’s leadership calls for a streamlined regulatory framework as India gears to scale in cell and gene therapy. Executives from the German group also talked to Scrip about helping advance local capabilities, delivering point-of-care CAR- T cell therapy to hospitals and pricing dynamics.
• By
Servier takes a Phase I rationally designed cancer candidate for $70m up front, while Black Diamond will wait on more mature data for its Phase II lead candidate in lung cancer.
• By
Deal Snapshot: The antibody-drug conjugate field continues one of the hottest dealmaking spaces and Roche continues to invest heavily. Its latest pact could be transformative for the UK firm which already has a decent number of big pharma partners.